ANZGOG ASM 2025

The most common TEAEs that occurred in >30% patients treated with JEMPERLI plus CP vs CP at 36.6 months follow-up were nausea (54.4% and 46.3%), alopecia (53.9% and 50.0%), fatigue (52.3% and 54.9%), peripheral neuropathy (44.0% and 41.9%), anaemia (37.8% and 42.7%), arthralgia (37.3% and 35.4%), constipation (34.9% and 36.2%) and diarrhoea (31.5% and 29.3%). 1 The most common treatment-emergent irAEs for JEMPERLI + CP vs CP were hypothyroidism (12.0% vs 2.8%), rash (7.1% vs 2.0%), arthralgia (6.6% vs 6.5%), and increased alanine aminotransferase (6.2% vs 1.2%). 1 The first and only immunotherapy in combination with CP to demonstrate overall survival in dMMR advanced or recurrent endometrial cancer patients vs CP: 1 • JEMPERLI + CP demonstrated a 68% reduction in risk of death vs CP in dMMR patients 1†# † Median OS was not reached with JEMPERLI + CP vs 31.4 months CP in dMMR patients (HR=0.32, 95% CI: 0.17-0.63, nominal P=0.0002; prespecified exploratory endpoint, median 36.6 months follow-up). 1 # Median PFS for JEMPERLI + CP not reached vs 7.7 months for CP in dMMR patients (HR 0.28, 95% CI: 0.16-0.50, P<0.0001; primary endpoint, median 24 months follow-up). 2,3

NOW PBS LISTED 4

Scan the QR code to learn more about JEMPERLI

JEMPERLI (dostarlimab) is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent dMMR/MSI-H endometrial cancer. 2 PBS LISTED: JEMPERLI Authority Required (STREAMLINED). Refer to PBS Schedule for full information. Please review product information before prescribing. Product information is available at www.gsk.com.au/jemperli or by scanning the QR code. ▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems Abbreviations: CI , confidence interval; CP, carboplatin-paclitaxel; dMMR , mismatch repair deficient; HR , hazard ratio; irAE , immune-related adverse event; MSI-H , microsatellite instability-high; OS, overall survival; PBS , Pharmaceutical Benefits Scheme; PD-1 , programmed cell death protein 1; PFS , progression-free survival; TEAE , treatment-emergent adverse event. References: 1. Powell MA, et al. Ann Oncol. 2024;35(8):728-738. 2. JEMPERLI Product Information. 3 . Mirza MR, et al. N Engl J Med. 2023;388(23):2145-2158 4. Pharmaceutical Benefits Scheme. Dostarlimab. www.pbs.gov.au. For information on GSK products or to report an adverse event involving a GSK product, please contact GSK Medical Information on 1800 033 109. Trademarks are owned by or licensed to the GSK group of companies © 2025 GSK group of companies or its licensor. GlaxoSmithKline Australia Pty Ltd. Melbourne VIC. PM-AU-DST-JRNA-250001. Date of Approval February 2025.